RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Erytech Pharma Stock

Erytech Pharma ROA 2024

Erytech Pharma ROA

-0.46

Ticker

PHXM.PA

ISIN

FR0011471135

WKN

A1T94R

In 2024, Erytech Pharma's return on assets (ROA) was -0.46, a 9,098.23% increase from the -0 ROA in the previous year.

Erytech Pharma Aktienanalyse

What does Erytech Pharma do?

Erytech Pharma SA is a biopharmaceutical company specializing in the development of innovative therapies for the treatment of rare and severe diseases. Founded in 2004, the company is headquartered in Lyon, France and currently employs over 250 employees. Erytech Pharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding Erytech Pharma's Return on Assets (ROA)

Erytech Pharma's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Erytech Pharma's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Erytech Pharma's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Erytech Pharma’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Erytech Pharma stock

What is the Return on Assets (ROA) of Erytech Pharma this year?

The Return on Assets (ROA) of Erytech Pharma is -0.46 undefined this year.

What was the ROA of Erytech Pharma compared to the previous year?

The ROA of Erytech Pharma has increased by 9,098.23% compared to the previous year.

What consequences do high ROA have for investors of Erytech Pharma?

A high ROA is advantageous for investors of Erytech Pharma, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in Erytech Pharma?

A low ROA can be unfavorable for investors of Erytech Pharma as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of Erytech Pharma affect the company?

An increase in ROA of Erytech Pharma can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of Erytech Pharma impact the company?

A reduction in the ROA of Erytech Pharma can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of Erytech Pharma?

Some factors that can influence the ROA of Erytech Pharma include revenue, operating costs, asset structure, and industry average.

Why is the ROA of Erytech Pharma important for investors?

The ROA of Erytech Pharma is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can Erytech Pharma take to improve ROA?

To improve ROA, Erytech Pharma can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does Erytech Pharma pay?

Over the past 12 months, Erytech Pharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Erytech Pharma is expected to pay a dividend of 0 EUR.

What is the dividend yield of Erytech Pharma?

The current dividend yield of Erytech Pharma is .

When does Erytech Pharma pay dividends?

Erytech Pharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Erytech Pharma?

Erytech Pharma paid dividends every year for the past 0 years.

What is the dividend of Erytech Pharma?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Erytech Pharma located?

Erytech Pharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von Erytech Pharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Erytech Pharma from 10/2/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 10/2/2024.

When did Erytech Pharma pay the last dividend?

The last dividend was paid out on 10/2/2024.

What was the dividend of Erytech Pharma in the year 2023?

In the year 2023, Erytech Pharma distributed 0 EUR as dividends.

In which currency does Erytech Pharma pay out the dividend?

The dividends of Erytech Pharma are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Erytech Pharma

Our stock analysis for Erytech Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Erytech Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.